Research and Development
Biopharmaceuticals play an important role in the treatment and prevention of serious diseases and as such, its demand has been steadily increasing. With the consecutive outbreak of recent diseases over the last few years, biopharmaceuticals are needed more than ever. Successful production of biopharmaceutical could lead to an improved quality of life, a cure for serious diseases and for some patients, a second chance in life. Advances in science and technology enabled us to grasp a deeper understanding of diseases and in turn, allows the discovery and development of potential drugs. While millions of people could benefit from biopharmaceuticals, its research and development (R&D) is a long and complex process. The whole R&D process is very time-consuming and rigorous as it requires highly qualified researchers and appropriate technologies.
For the initial stages of R&D, efficiency and effectiveness of production are often optimized. The type of technology used is also critical as it will set the pace and overall yield and quality of production. For biopharmaceuticals that are derived from microorganisms, adherent cells or suspended cells, a specific bioreactor must be used for each mentioned type of cells. Adherent cells are usually cultured in systems such as roller bottles, t-flasks, and packed bed bioreactors, while microorganisms and suspended cells are cultured in shakers or stirred tank bioreactors. While bioreactors are continuously improved for efficient production of adherent cells and suspension cells, most bioreactors are only capable of supporting the growth of either adherent cells or suspension cells.
VacciXcell™ Hybrid Bioreactor
The VacciXcell™ Hybrid Bioreactor is a laboratory scale bioreactor system ideal for biopharmaceutical companies who are in the initial stages of R&D and are looking to determine the effectiveness, productivity and feasibility of the mammalian cells, whether as suspended or adherent cells. It is capable of supporting both the growth of suspension and adherent cells and performing fermentation. For start-up biopharmaceutical companies who want to know which cell line-to -bioreactor combination will have the best yield, VacciXcell™ Hybrid Bioreactor is a more practical bioreactor due to its dual features as it is costly to try different bioreactors for different types of cells used in cell culture. The VacciXcell™ Hybrid Bioreactor applies the tide motion principle and stir principle, both of which were also behind the technology of its predecessors, CelCradle™ and StirCradle™, respectively.
The adherent cells attach to carriers which are contained within the matrix vessel and are alternately exposed to nutrition and aeration. Microorganisms and suspended cells are cultured under the stir principle wherein an impeller stirs the cells suspended in culture medium. Switching from adherent culture to suspension culture can be done by interchanging the matrix vessel and impeller within its reactor vessel.